Mistletoe treatment for cancer review of controlled trials in humans.
暂无分享，去创建一个
[1] S. Joshi,et al. From ill-defined extracts to the immunomodulatory lectin: will there be a reason for oncological application of mistletoe? , 1994, Planta medica.
[2] R. Angeli,et al. Complete anuria in unilateral renal artery obstruction and ischemic nephropathy , 1991 .
[3] W. Jungi,et al. [Why do cancer patients use alternative medicine?]. , 1991, Schweizerische medizinische Wochenschrift.
[4] K. Frei,et al. Increased Secretion of Tumor Necrosis Factor α, Interleukin 1, and Interleukin 6 by Human Mononuclear Cells Exposed to β-Galactoside-specific Lectin from Clinically Applied Mistletoe Extract , 1990 .
[5] H. Gabius,et al. Modulatory potency of the beta-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. , 1989, Cancer research.
[6] R. Oldham. Biological response modifiers. , 1983, Journal of the National Cancer Institute.
[7] L. Havelec,et al. Rezidivprophylaxe bei operierten Bronchuskarzinompatienten mit dem Mistelpräparat Iscador® – Ergebnisse eines klinischen Versuchs aus den Jahren 1969–1971 , 1978 .
[8] K. E. Fellmer. A clinical trial of Iscador , 1968, British Homeopathic Journal.